Share
5 min read
researchEvidence-based

Revolutionary Statistical Models Reveal 43% of "Failed" Alzheimer's Trial Patients Actually Improved

This changes EVERYTHING about clinical trials...

T
· Reviewed by Dr. Kevin Tran, PharmD

Key takeaways · TL;DR

43 percent of patients in a 'failed' Alzheimer's trial actually improved dramatically, with treatment effects DOUBLE what approved drugs achieve, according to Dr. Lei Liu at Washington University using machine learning on old trial data (AAIC 2025). Drugs dismissed as failures might work perfectly for APOE4 carriers, and APOE4-specific trials can now be 60 to 70 percent smaller, making precision medicine for carriers feasible now rather than in a distant future.

Definition

A statistical approach that finds patient subgroups within a trial where a treatment's effect is much larger than the overall average.

Traditional trial analysis reports a single average treatment effect, which can hide large benefits for specific patient types. Subgroup identification uses machine learning or advanced statistical methods to uncover these hidden responders. For APOE4 carriers, subgroup identification can reveal that a 'failed' drug works dramatically well for our genotype, opening paths to approval or compassionate use. The FDA has been actively supporting these methods, signaling a shift toward precision medicine in Alzheimer's research.

Hi Phoenix friends,

I just analyzed presentations from 6 different research teams at AAIC 2025, and what they discovered will blow your mind:

43% of patients in a "FAILED" Alzheimer's trial actually improved dramatically - their treatment effects were DOUBLE what approved drugs achieve. They were just hidden when all patients got averaged together.

Think about what this means for us:

- Drugs dismissed as failures might work perfectly for APOE4 carriers

- Trials specifically for our genetic profile are becoming feasible (60-70% smaller!)

Dr. Lei Liu from Washington University proved this using machine learning on old trial data. The FDA is actively supporting these approaches - they just approved new imaging guidelines last month.

I break down all 6 breakthroughs in this Youtube video

Key takeaway: We're not waiting for miracles anymore. The math proves that precision medicine for APOE4 carriers is happening NOW.
And this is what we are building towards with the Phoenix Community.

Credits: Alzheimer's Association International Conference 2025

Session Chair(s): Sue Jane Wang (Division of Biometrics I, US Food and Drug Administration, MD, USA)Heather M. Snyder (Alzheimer's Association, IL, USA)

Session Presenter: Lei Liu (Division of Biostatistics, Washington University in St Louis, MO, USA) - Subgroup Identification in Alzheimer’s Disease Trial

Viswanath Devanarayan (Eisai Inc., NJ, USA; University of Illinois Chicago, IL, USA) - Baseline predictions of PACC progression trajectories in preclinical AD improve the precision and power of treatment effect assessments

Yan Li (Washington University in St. Louis, MO, USA) - Primary Endpoint and Analysis Model for Prevention Trials with Participants with Preclinical AD: Lessons Learned from the DIAN-TU Platform Trial

Kun Jin (Anavex Life Sciences Corp., NY, USA) - A Novel Linear B-Spline Mixed Effect Model for Alzheimer’s Disease Clinical Study Data

Jinglin Zhong (Alector, CA, USA) - Beyond A Single Study Visit: Lesson Learned from the AD Clinical Trials

John Lawrence (Division of Biometrics I, US Food and Drug Administration, MD, USA) - Discussion of Perspectives on Various Innovative Statistical Methodologies for Alzheimer’s Disease Clinical Trials

Filed under
researchcognition

Discussion

Join the conversation

Your email will never be published. Be respectful and constructive.

FAQ

Frequently asked questions.

Why do 'failed' Alzheimer's drug trials sometimes hide working treatments?
Standard trial analysis averages all patients together, which can mask large benefits in specific subgroups. Dr. Lei Liu at Washington University used machine learning to re-analyze old Alzheimer's trial data and found 43 percent of patients in a trial previously declared a failure actually improved dramatically, with treatment effects DOUBLE what currently approved drugs achieve (AAIC 2025). These responders were hidden when averaged with non-responders. This has profound implications for APOE4 carriers because drugs dismissed as industry-wide failures might be highly effective for the specific APOE4 subgroup, and the machine learning methods to identify these responders are now being supported by the FDA with new imaging guidelines.
Can APOE4 carriers get smaller, more targeted Alzheimer's clinical trials?
Yes, and this is one of the most important developments for the APOE4 community. Research presented at AAIC 2025 shows that trials specifically recruiting APOE4 carriers can be 60 to 70 percent smaller than standard trials while producing the same statistical power. This is because variance within an APOE4-only cohort is lower than mixed-genotype cohorts, making treatment effects easier to detect. Smaller trials mean lower costs, faster recruitment, and more willingness from sponsors to test APOE4-specific hypotheses. For carriers frustrated by one-size-fits-all dementia research, this is a real and near-term shift toward precision medicine tailored to our genotype.
How does machine learning find responders in Alzheimer's trial data?
Machine learning techniques analyze patient-level characteristics (biomarkers, demographics, genetics, disease stage) to identify subgroups where a treatment's effect is much larger than the overall average. Unlike traditional statistical methods that test one variable at a time, ML can find complex interactions that a researcher would not think to test. Dr. Lei Liu's work used these methods on old trial data and found subgroups where the same drug produced dramatic benefits. For APOE4 carriers, this opens the possibility that past failures are not failures at all for us, and drugs may get re-examined and approved for the APOE4 subpopulation specifically.
Is the FDA supporting APOE4-specific drug approval pathways?
Yes. Research presented at AAIC 2025 noted that the FDA actively supports subgroup-identification approaches and recently approved new imaging guidelines that enable more precise patient stratification. The broader message from the conference is that precision medicine for Alzheimer's is shifting from aspiration to execution, with regulators, researchers, and pharma companies aligning on the need for genotype-stratified trials. For APOE4 carriers specifically, this means more trials recruiting carriers explicitly, more analyses breaking out carrier subgroups from existing data, and potentially faster paths to approved treatments that work for our genetics even if they failed for the general population.
Keep reading

Related protocols.